The following list of cancer immunotherapies are available for licensing under U.S. Patent Publication No.: 20220298491.

Pluripotent Stem Cell Derived Dendritic Cells and Engineered Dendritic Cells for Cancer Immunotherapy

Abstract
Disclosed are populations of dendritic cells generated from stem cells capable of inducing immunity towards cancer. In one embodiment said dendritic cells are generated from allogeneic inducible pluripotent stem cells, for some uses, said pluripotent stem cells are genetically engineered/edited to induce cancer specific immunity and/or resist immunosuppressive effect of tumor derived microenvironment. In one embodiment pluripotent stem cells are transfected with cancer stem cell antigens such as BORIS and/or NR2F6.






Melanoma is a dangerous type of skin cancer that develops from melanocytes, the cells that produce melanin, the pigment that gives skin and hair their color.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Juvenile melanoma, also known as melanoma in children, is a rare but common skin cancer in children.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lentigo maligna melanoma is a type of skin cancer that develops from a lentigo maligna, a precancerous condition.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Malignant melanoma, also known as melanoma, is a dangerous type of skin cancer that can develop from melanocytes, the cells that produce melanin and give skin its color.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Acral-lentiginous melanoma is a specific type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Amelanotic melanoma, these skin lesions lack melanin, the dark pigment that gives most moles and melanomas their color. Instead, amelanotic melanomas can be clear, white or skin-colored, sometimes with a slight pink, purple or red tint.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Benign juvenile melanoma is an old term for a rare, noncancerous mole called a Spitz nevus.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Nodular melanoma subungal melanoma is a rare and aggressive form of skin cancer that can appear as a nodule under the nail.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Superficial spreading melanoma is a type of skin cancer that is the most common form of melanoma, accounting for 70–80% of cases.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%